DOXORUBICIN COMPARED WITH RELATED-COMPOUNDS IN A NUDE-MOUSE MODEL FOR HUMAN OVARIAN-CANCER

被引:18
作者
BOVEN, E
SCHLUPER, HMM
ERKELENS, CAM
PINEDO, HM
机构
[1] Department of Oncology, Free University Hospital, 1081 HV Amsterdam
关键词
D O I
10.1016/0277-5379(90)90626-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Eight human ovarian cancer lines grown in nude mice were used to compare the activity of doxorubicin, epirubicin, mitoxantrone and menogaril. The tumour lines were different in histological subtype, tumour doubling time and sensitivity to doxorubicin. The compounds were administered intravenously at the maximum tolerated dose twice with one week in between two tumours measured 50-150 mm3. Growth inhibition greater than 50% was obtained for doxorubicin in 8/8, for epirubicin in 4/8, for mitoxantrone in 5/8 and for menogaril in 2/8 tumour lines. In MRI-H-207, doxorubicin was the only drug able to induce complete remission. Compared with doxorubicin, mitoxantraone and menogaril were given in proportionally higher doses than those administered to patients, but did not result in superior antitumour activity.
引用
收藏
页码:983 / 986
页数:4
相关论文
共 25 条
  • [1] A RANDOMIZED MULTICENTER TRIAL COMPARING MITOXANTRONE, CYCLOPHOSPHAMIDE, AND FLUOROURACIL WITH DOXORUBICIN, CYCLOPHOSPHAMIDE, AND FLUOROURACIL IN THE THERAPY OF METASTATIC BREAST-CARCINOMA
    BENNETT, JM
    MUSS, HB
    DOROSHOW, JH
    WOLFF, S
    KREMENTZ, ET
    CARTWRIGHT, K
    DUKART, G
    REISMAN, A
    SCHOCH, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) : 1611 - 1620
  • [2] ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY
    BLUM, RH
    CARTER, SK
    [J]. ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) : 249 - 259
  • [3] BOVEN E, 1985, CANCER RES, V45, P86
  • [4] PRECLINICAL PHASE-II STUDIES IN HUMAN-TUMOR LINES - A EUROPEAN MULTICENTER STUDY
    BOVEN, E
    WINOGRAD, B
    FODSTAD, O
    LOBBEZOO, MW
    PINEDO, HM
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (03): : 567 - 573
  • [5] BOVEN E, 1986, CANCER CHEMOTH PHARM, V18, P124
  • [6] CARTER SK, 1979, CANCER TREAT REP, V63, P935
  • [7] EPIRUBICIN - A REVIEW OF THE PHARMACOLOGY, CLINICAL ACTIVITY, AND ADVERSE-EFFECTS OF AN ADRIAMYCIN ANALOG
    CERSOSIMO, RJ
    HONG, WK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) : 425 - 439
  • [8] PHASE-I STUDY OF INTRAVENOUS MENOGARIL ADMINISTERED INTERMITTENTLY
    DODION, P
    SESSA, C
    JOSS, R
    CRESPEIGNE, N
    WILLEMS, Y
    KITT, M
    ABRAMS, J
    FINET, C
    BREWER, JE
    ADAMS, WJ
    EARHART, RH
    ROZENCWEIG, M
    KENIS, Y
    CAVALLI, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (05) : 767 - 774
  • [9] DORR FA, 1986, CANCER RES, V46, P2562
  • [10] EHNINGER G, 1987, ROLE MITOXANTRONE MA, P19